Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?

Arthritis Research & Therapy

Edward M. Vital¹  Maya H. Buch¹  Vasco C. Romão²  João Eurico Fonseca² 

[1] Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds;Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa;

关键词: Personalised therapy;    Biological therapy;    Rheumatoid arthritis;    Response predictors;    Biomarkers;   

DOI  :  10.1186/s13075-017-1445-3

来源: DOAJ

【 摘 要 】

Abstract Individualising biologic disease-modifying anti-rheumatic drugs (bDMARDs) to maximise outcomes and deliver safe and cost-effective care is a key goal in the management of rheumatoid arthritis (RA). Investigation to identify predictive tools of bDMARD response is a highly active and prolific area of research. In addition to clinical phenotyping, cellular and molecular characterisation of synovial tissue and blood in patients with RA, using different technologies, can facilitate predictive testing. This narrative review will summarise the literature for the available bDMARD classes and focus on where progress has been made. We will also look ahead and consider the increasing use of ‘omics’ technologies, the potential they hold as well as the challenges, and what is needed in the future to fully realise our ambition of personalised bDMARD treatment.

【 授权许可】

Unknown